Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Apyx Medical Inc (APYX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: APYX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4
1 Year Target Price $4
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.97% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.04M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 3 | Beta 1.2 | 52 Weeks Range 0.76 - 2.30 | Updated Date 07/1/2025 |
52 Weeks Range 0.76 - 2.30 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -42.37% | Operating Margin (TTM) -32.35% |
Management Effectiveness
Return on Assets (TTM) -14.6% | Return on Equity (TTM) -129.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 92941243 | Price to Sales(TTM) 1.8 |
Enterprise Value 92941243 | Price to Sales(TTM) 1.8 | ||
Enterprise Value to Revenue 1.97 | Enterprise Value to EBITDA -5.33 | Shares Outstanding 37793900 | Shares Floating 25501425 |
Shares Outstanding 37793900 | Shares Floating 25501425 | ||
Percent Insiders 14.56 | Percent Institutions 43.51 |
Analyst Ratings
Rating 2 | Target Price 4 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Apyx Medical Inc
Company Overview
History and Background
Apyx Medical, formerly Bovie Medical, develops and markets energy-based surgical products. Founded in 1921 as the Bovie Company, later renamed Bovie Medical, then Apyx Medical. Historically focused on electrosurgical generators and accessories, the company shifted its focus to its Renuvion technology in recent years.
Core Business Areas
- Energy-Based Surgical Solutions: Development, manufacturing, and sale of proprietary Helium Plasma Technology (HPT) surgical products marketed under the Renuvion brand. Primarily used in cosmetic surgery and general surgery for tissue coagulation and skin contraction.
Leadership and Structure
Apyx Medical is led by Charlie Goodwin (CEO). The company has a board of directors overseeing its strategy and operations. The organizational structure is typically aligned with functional departments such as Sales, Marketing, R&D, and Operations.
Top Products and Market Share
Key Offerings
- Renuvion: Renuvion is Apyx Medical's flagship product, utilizing helium plasma technology for subdermal coagulation and skin contraction. The competitors for this product are BodyTite by InMode (INMD), EmbraceRF by InMode (INMD) and ThermiRF. Market share information is not easily available, but Renuvion is considered a growing competitor in the energy-based cosmetic surgery market. Revenue from this product makes up a significant portion of the company's revenue.
Market Dynamics
Industry Overview
The surgical and aesthetic energy-based device market is experiencing growth due to increasing demand for minimally invasive procedures, technological advancements, and an aging population. Key trends include the integration of artificial intelligence, robotics, and advanced imaging technologies.
Positioning
Apyx Medical is positioned as a player in the energy-based surgical and aesthetic market with Renuvion technology. It aims to capture market share with its minimally invasive and effective solutions.
Total Addressable Market (TAM)
The global surgical and aesthetic energy-based device market is estimated to be worth billions of dollars annually. Apyx Medical is positioning itself to capture a portion of this TAM with Renuvion and other potential product offerings. TAM estimations for the minimally invasive surgery are estimated at $20B by 2030.
Upturn SWOT Analysis
Strengths
- Proprietary Renuvion technology
- Minimally invasive solution
- Growing market adoption in aesthetics
- Strong brand recognition for Renuvion
Weaknesses
- Reliance on a single key product
- Limited market share compared to larger competitors
- Regulatory risk related to new applications
- Profitability concerns.
Opportunities
- Expanding applications of Renuvion in other surgical fields
- Geographic expansion into new markets
- Strategic partnerships and collaborations
- Development of new energy-based devices
Threats
- Competition from established players with deeper pockets
- Technological advancements by competitors
- Changes in regulatory landscape
- Economic downturn affecting consumer spending on elective procedures
Competitors and Market Share
Key Competitors
- INMD
Competitive Landscape
Apyx Medical competes with larger companies that have broader product portfolios and greater financial resources. Apyx Medical's competitive advantage lies in its proprietary Renuvion technology.
Growth Trajectory and Initiatives
Historical Growth: Apyx Medical has experienced revenue growth in recent years, driven by increased adoption of Renuvion. However, profitability remains a challenge.
Future Projections: Analysts project continued revenue growth for Apyx Medical based on Renuvion's market potential. Profitability improvements are crucial for sustainable growth.
Recent Initiatives: Recent initiatives include expanding the sales force, launching new marketing campaigns, and pursuing regulatory approvals for new Renuvion applications.
Summary
Apyx Medical shows promise with its innovative Renuvion technology and potential for growth within the aesthetic surgery market. While the company faces challenges due to its limited product portfolio and profitability concerns, it has opportunities to expand Renuvion's applications and enter new markets. Key areas to watch include sales execution, regulatory developments, and the ability to achieve sustainable profitability. Management will need to focus on product diversification to sustain the companies growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apyx Medical Inc
Exchange NASDAQ | Headquaters Clearwater, FL, United States | ||
IPO Launch date 1987-01-01 | President, CEO & Director Mr. Charles D. Goodwin II | ||
Sector Healthcare | Industry Medical Devices | Full time employees 220 | Website https://apyxmedical.com |
Full time employees 220 | Website https://apyxmedical.com | ||
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.